

## **CURRICULUM VITAE**

### **PERSONAL DATA**

Name: Judith M. Connett

### **EDUCATION**

1964-1968 University of Chicago, Chicago, Illinois; B.A. Political Science  
1973-1979 Washington University, St. Louis Missouri; Ph.D. Immunology

### **POSTDOCTORAL TRAINING**

1979-1981 Post-Doctoral Fellow, Laboratory of Dr. Paul Bornstein, Department of Biochemistry, University of Washington, Seattle, Washington

### **ACADEMIC APPOINTMENTS**

1982-1984 Research Instructor, Jewish Hospital, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri  
1985-2002 Research Assistant Professor, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri  
2002-2003 Assistant Research Scientist, Department of Surgery, University of Michigan, Ann Arbor, Michigan  
2004-2006 Research Assistant Professor, Department of Surgery, University of Michigan, Ann Arbor, Michigan  
2006- Research Assistant Professor, Department of Pathology, University of Michigan, Ann Arbor, Michigan

### **CONSULTING POSITIONS**

1997-2002 Genzyme Corporation, Cambridge, Massachusetts

### **SCIENTIFIC ACTIVITIES**

2001-2002 Reviewer, Cancer Biotherapy and Radiopharmaceuticals

**GRANT SUPPORT**

**Funding Agency:** NCI/NIH  
**Period:** 2/01/88 - 7/31/95  
**Research Title:** Tumor Localization and Imaging Using Colon Cancer Monoclonal Antibodies  
**Fund Number:** RO1 CA 44728-01-07  
**Principal Investigator:** Gordon W. Philpott M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$1,967,691

**Funding Agency:** Barnes Jewish Foundation  
**Period:** 12/31/90 - 12/31/2000  
**Research Title:** Radiolabeled Monoclonal Antibodies as Targeting and Therapeutic Agents for Cancer.  
**Fund Number:** BJH 4260  
**Principal Investigators:** Gordon W. Philpott, M.D., Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$1,044,825

**Funding Agency:** NIH  
**Period:** 12/31/90 - 12/31/2002  
**Grant Title:** Targeted Metal Chelators for Diagnostic Imaging.  
**Fund Number:** 2RO1 CA42925-12  
**Principal Investigator:** Michael J. Welch, Ph.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Annual Direct Costs:** \$37,360

**Funding Agency:** US DOE  
**Period:** 8/1/96 - 7/31/99  
**Grant Title:** Radiation Dosimetry of CU-64 Labeled Radiotherapy Agents  
**Grant Number:** DEFG0294ER62216  
**Principal Investigator:** Michael J. Welch, Ph.D.  
**Co-investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$29,826

**Funding Agency:** Jewish Foundation  
**Period:** 1/1/96-12/31/96  
**Research Title:** Radioimmunotherapy with Cu-64-labeled MAbs and Fragments in a Pre-clinical Human Colon Cancer Model.  
**Fund Number:** JHFR 2870-01  
**Principal Investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$50,000

**Funding Agency:** Jewish Foundation  
**Period:** 1/1/97-12/31/99  
**Research Title:** Positron Emission Tomography and Radioimmunotherapy with Radiolabeled Monoclonal Antibodies Reactive with Breast Cancer in Pre-clinical Animal Models.  
**Fund Number:** JHFR 2870-03  
**Principal Investigator:** Judith M. Connett, Ph.D  
**Total Direct Costs:** \$100,000

**Funding Agency:** Jewish Foundation  
**Period:** 1/1/98-12/31/98  
**Grant Title:** Relationship Between Intra-Abdominal Solid Tumor Manipulation and Tumor Implantation at Abdominal Wall Trocar Sites in a Hamster.  
**Fund Number:** JHFR 5134-01  
**Principal Investigator:** James W. Fleshman, M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$45,956

**Funding Agency:** Genzyme Corporation  
**Period:** 9/23/98 - 10/24/99  
**Grant Title:** The Effects of Genzyme 's Proprietary Septrafilm Product in the Seeding of GW39 Colorectal Cancer Cells in a Hamster Model of Trocar Site Seeding  
**Fund Numbers:** 5184-00  
**Principal Investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$26,296

**Funding Agency:** Genzyme Corporation  
**Period:** 10/25/99 - 10/25/00  
**Grant Title:** Effects of Septrafilm on Tumor Growth in Hamsters  
**Fund Numbers:** 5392-00  
**Principal Investigator:** Judith M. Connett, Ph.D.  
**Total Direct Costs:** \$48,750

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/99 - 12/31/99  
**Grant Title:** Radioimmunotherapy of GW39 tumors in a Hamster Micrometastatic Model Using <sup>131</sup>I-MAb 1A3  
**Grant Number:** 22-4175-34415D  
**Principal Investigator:** Judith M. Connett, Ph.D.

Annual Direct Costs: \$11,753

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/99 - 12/31/99  
**Grant Title:** Does Solid Tumor Manipulation Cause Tumor Implants in Abdominal Wounds?  
**Grant Number:** 22-4175-34415E  
**Principal Investigator:** James Fleshman, M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Annual Direct Costs:** \$34,391

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/99 - 12/31/99  
**Grant Title:** Does Solid Tumor Manipulation Cause Tumor Implants in Abdominal Wounds: Phase II  
**Grant Number:** 22-4175-34415G  
**Principal Investigator:** James Fleshman, M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Annual Direct Costs:** \$35,972

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/99 - 12/31/99  
**Grant Title:** Definitive study of the influence of tumor inoculum on the implantation of tumor at trocar sites during laparoscopy.  
**Grant Number:** 22-4175-34415F  
**Principal Investigator:** James Fleshman, M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Annual Direct Costs:** \$13,895

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/00 - 12/31/00  
**Grant Title:** Influence of Helium Pneumoperitoneum on tumor implantation at trocar sites.  
**Grant Number:** 22-4175-46016A  
**Principal Investigator:** James Fleshman, M.D.  
**Co-Investigator:** Judith M. Connett, Ph.D.  
**Annual Direct Costs:** \$15,520

**Funding Agency:** Washington University Minimally Invasive Surgery  
**Period:** 1/1/97- 12/31/97  
**Grant Title:** Inhibition of tumor Implants by Sodium Hyaluronate-Based Bioresorbable Membrane (Septrafilm)  
**Grant Number:** 22-4175-34415  
**Principal Investigator:** James Fleshman, M.D.

Co-Investigator: Judith M. Connett, Ph.D.  
Annual Direct Costs: \$11,945  
**Funding Agency:** Barnes Jewish Foundation  
Period: 1/1/99 - 12/31/01  
Grant Title: Interferon Regulatory Factors 1 and 2 Expression in Human  
Cancer Cell Lines and Human and Mouse Tumors  
Fund Number: BJH 5419  
Principal Investigator: Judith M. Connett, Ph.D.  
Total Direct Costs: \$90,000  
Percent of Effort: 25

**Funding Agency:** The Harris Foundation  
Period: 12/31/00 - 12/31/01  
Grant Title: The Inhibition of Colon Cancer Cell Implantation at Wound  
Sites  
Fund Number: BJH 4260  
Principal Investigator: Judith M. Connett, Ph.D.  
Total Direct Costs: \$50,000  
Percent of Effort: 20

**Funding Agency:** Susan G. Komen Breast Cancer Foundation  
Period: 10/1/01 - 9/31/03  
Grant Title: The Role of Fas and Fas Ligand in Interferon Gamma Mediated  
Growth Inhibition and Apoptosis in Human Breast  
Fund Number: BJH 5855  
Principal Investigator: Judith M. Connett, Ph.D.  
Total Direct Costs: \$200,000  
Percent of Effort: 25

**Funding Agency:** The Harris Foundation  
Period: 1/31/02 - 12/31/02  
Grant Title: Interferon Regulatory Factors 1 and 2 Expression in Human  
Cancer Cell Lines and Human and Mouse Tumors  
Fund Number: BJH 4260  
Principal Investigator: Judith M. Connett, Ph.D.  
Total Direct Costs: \$125,000  
Percent of Effort: 25

**Funding Agency:** Department of Surgery, University of Michigan  
Research Advisory Committee Grant  
Period: 08/01/04 -08/31/2014  
Grant Title: The Role of Interferon-gamma in Fas Mediated Apoptosis  
Fund Number: U013242

Principal Investigator: Judith M. Connett, Ph.D.  
 Total Direct Costs: \$25,000  
 Percent of Effort: 60

**Funding Agency:** University of Michigan Dean's Initiative Grant  
**Period:** 01/01/06-12/31/08  
**Grant Title:** Determine biomarkers important in diagnosing sepsis at early stages and developing a bedside assay for sepsis evaluating these markers.

Fund Number: 3100402  
 Principal Investigator: Daniel Remick, M.D.  
 Total Direct Costs: \$450,000  
 Percent of Effort: 80

#### **CERTIFICATION AND LICENSURE**

None

#### **MILITARY SERVICE**

None

#### **MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES**

1976-2005	American Association for the Advancement of Science
1988-1999	Society of Nuclear Medicine
1997-2005	American Association for Cancer Research
2002-2005	International Society for Interferon and Cytokine Research

## TEACHING ACTIVITIES

### *Mentoring*

During the past 20 years many residents have spent one to two years in the laboratory engaged in research. It was my responsibility to oversee and help with the resident research projects as well as teach these young doctors scientific methods and stimulate their intellect through regular journal club meetings and library searches on relevant topics, followed by discussions and lab meetings. These include:

Richard Wahl, M.D.	1981-1982
Todd Garvin, M.D.	1983-1985
James Fleshman, M.D.	1984-1985
Alan Timmcke, M.D.	1986-1987
Jeffrey Fenwick, M.D.	1987-1989
Lawrence O'Halloran, M.D.	1990-1991
Steve Shumura, M.D.	1991-1992
Tim Kaiser, M.D.	1992-1993
Daniel Jones, M.D.	1994-1995
Justin S. Wu, M.D.	1995-1996
Robert Underwood, M.D.	1997-1999
Valerie Halpin, M.D.	2000-2001
Steven Hunt, M.D.	2000-2001
Emily Winslow, M.D.	2001-2003
Brian Saunders, M.D.	2003-2005

The following physicians have worked in the laboratory during a sabbatical from their positions abroad:

David Neufeld, M.D.	1987-1988	Israeli surgeon
Eli Shemesh, M.D.	1987-1988	Israeli surgeon
Eunice Lee, M.D.	2001-2002	Korean physician
Byung Kim, M.D.	2001-2003	Korean physician

During every summer for the past 20 years, college undergraduates and medical students have found places in the lab working on projects. I have cherished the opportunities and challenges that these students have afforded me, and believe that most have left the lab having learned something about both the joys and frustrations of science at the bench, how to design carefully controlled experiments, and how to read scientific papers critically.

During the 2000-2001 period I supervised the Master's thesis work and writing of Aymen Elfiky, a medical student at Washington University School of Medicine.



From 1999-2002 I participated in an annual seminar with medical students on the expectations of cancer patients when they interact with physicians.

Over the past 20 years, I have organized and been a participant in many journal clubs and I have given many seminars on my own work and on topics of interest to me.

While in the lab of Dr. Dan Remick I mentored both undergraduate and graduate students

### **EXTRAMURAL PRESENTATIONS**

1. Characterization of the binding properties of murine monoclonal antibody (MAb) 1A3, a newly described antibody displaying anti-human colon cancer selectivity. American Association for Cancer Research Annual Meeting, Atlanta, GA, 1987.
2. Further characterization of murine monoclonal antibody (MAb) 1A3, and antibody displaying anti-human colon cancer selectivity. American Association for Cancer Research Annual Meeting, New Orleans, LA, 1988.
3. Increased uptake of a unique radiolabeled anti-colon cancer monoclonal antibody (MAb 1A3) in young tumors in a human colon cancer (GW39) xenograft model. American Association for Cancer Research Annual Meeting, San Francisco, CA, 1989.
4. *In vitro* and *in vivo* characterization studies of anti-human colon cancer murine monoclonal antibodies (MAb) 1A3 and 5A4. American Association for Cancer Research Annual Meeting, San Francisco, CA, 1989.
5. Improved tumor uptake with a mixture of I-125 monoclonal antibodies in a colon cancer model. American Association for Cancer Research Annual Meeting, Washington, D.C., 1990.
6. Radioimmunotherapy of human colon carcinoma (GW39) in hamsters with <sup>131</sup>I- anti-colon cancer monoclonal antibody (MAb) 1A3. American Association for Cancer Research Annual Meeting, Houston, TX, 1991.
7. Tumor comparison of <sup>125</sup>I- and <sup>64</sup>Cu-anti-colorectal cancer monoclonal antibody 1A3 (MAb 1A3) in a human colon cancer (GW39) animal model. American Association for Cancer Research Annual Meeting, San Diego, CA, 1992.
8. Cu-67 and Cu-64 labeled monoclonal antibody (MAb) 1A3 as potential agents for radioimmunotherapy. Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, 1993.
9. Radioimmunotherapy of Human colon carcinoma (GW39) in hamsters with Cu-67 anti

- colon cancer monoclonal antibody (MAb) 1A3. American Association for Cancer Research Annual Meeting, San Francisco, CA, 1994.
10. *In vivo* toxicity and long-term radioimmunotherapy studies of Cu-64 and Cu-67 anti-colon carcinoma monoclonal antibody (MAb)-1A3 in the GW39-hamster model. Society of Nuclear Medicine Annual Meeting, Minneapolis, MN, 1995.
  11. Long-term radioimmunotherapy studies of Cu-64 anti-colon carcinoma monoclonal antibody (MAb)-1A3, intact and F(ab')<sub>2</sub>, singly and in combination, in the GW39-hamster model. Society of Nuclear Medicine Annual Meeting, Denver, CO, 1996.
  12. *In vivo* toxicity and radioimmunotherapy studies comparing Cu-64- and I-131-labeled anti-colon carcinoma monoclonal antibody (MAb)-1A3 in the GW39-hamster model. Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, June, 1998.
  13. Maximum tolerated dose studies in hamsters with Cu-64-BAT-2IT MAb 1A3, an anti-human colorectal cancer MAb. World Federation of Nuclear Medicine Biology and European Association of Nuclear Medicine Meeting, Berlin, August 30-Sept 4, 1998
  14. Radioimmunotherapy with Cu-64-labeled MAb 1A3 in hamsters carrying large, 7 day, GW-39 human colon cancer tumors. Seventh Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, Oct 15-17, 1998.
  15. Effects of Seprafilm on tumor implantation at trocar sites, preliminary results. Genzyme Corporation, Cambridge, MA, August, 1999.
  16. Effects of Seprafilm on tumor implantation at trocar sites. 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, Berlin, Germany, April 14-15, 2000.
  17. Implantation of GW39 human colon cancer cells at hamster wound sites as a function of cell inoculum and seprafilm barriers. 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, Berlin, Germany, April 14-15, 2000.
  18. Radioimmunotherapy of GW39 human colon cancer cells in a laparoscopic surgery hamster model. 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, Berlin, Germany, April 14-15, 2000.
  19. Effects of Seprafilm on a cecectomy model of human colon cancer. American Society of Colon and Rectal Surgeons Annual Meeting, Boston, Massachusetts, June 24-29, 2000.
  20. Review of recent studies in the hamster laparoscopic and cecectomy models using

Seprafilm. Genzyme Corporation, Cambridge, MA, June 28, 2000.

21. Interferon-gamma upregulation of Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. International Symposium on Cancer Vaccines, New York, NY, Oct 2-4, 2000.
22. Serial evaluation of radiotherapy of GW39 tumor bearing hamsters using PET/MRI. Workshop on MR in Experimental & Clinical Cancer Research in the New Millennium, Norway, 2000.
23. Interferon-gamma upregulation of Stat1 and Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. Meeting of the American Association of Cancer Research, New Orleans, LA, March 24-28, 2001.
24. Combined Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) characterization of abdominal tumors in a hamster laparoscopic model of colorectal cancer. 5<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, Zurich, Switzerland April 6-7, 2001.
25. <sup>64</sup>Cu-PTSM as an inhibitor of tumor recurrence in a colorectal cancer laparoscopic model. 5<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, Zurich, Switzerland April 6-7, 2001.
26. Expanded Studies of Interferon-gamma upregulation of Stat1 and Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. Meeting of the International Society for Interferon and Cytokine Research, Cleveland, OH, Oct 7-11, 2001.
27. MRI and PET Characterization of Abdominal Tumors in a Hamster Model of Colorectal Cancer. International Society for Magnetic Resonance in Medicine, Annual Meeting, Glasgow, Scotland, April, 2001.
28. MRI and microPET Imaging of Tumor Progression in Hamster Abdomens Following Laparoscopic Surgery and Radiotherapy. High Resolution Imaging in Small Animals: Instrumentation, Application and Animal Handling, Rockville, Maryland, Sept 9-11, 2001.
29. Cu-64 PTSM for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and MRI. 6<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, New York, New York, March 14-17, 2002.
30. Effect of intraperitoneal fibrinolytic therapy on tumor implantation in wound sites. 6<sup>th</sup>

International Conference of Experimental Laparoscopic Surgery, New York, New York, March 14-17, 2002.

31. Confocal microscopy detection of STAT1 and IRF-1 and -2 up regulation by *ex vivo* IFN- $\gamma$  in fresh human breast cancer tissue. Meeting of the American Association of Cancer Research, San Francisco, CA, April 6-10, 2002.
32. Interferon- $\gamma$  priming of breast cancer cell lines in Fas death receptor mediated apoptosis. Meeting of the American Association of Cancer Research, Orlando, FL, March 27-31, 2004.
33. Interferon- $\gamma$  priming of breast cancer cell lines in Fas and TRAIL death receptor mediated apoptosis. 5<sup>th</sup> Joint Meeting of the International Cytokine Society and International Society for Interferon and Cytokine Research. San Juan, Puerto Rico, October 21-25, 2004.
34. Examining the mechanism of Fas-mediated apoptotic resistance in MDA-231 breast cancer cells. Regulation of Cell Death in Oncogenesis. Waikoloa, HI, January 26-30, 2005.

## **INTRAMURAL PRESENTATIONS**

Yearly presentation of research results within the Department of Surgery and also in the Department of Radiation Sciences at Washington University.

The following presentations were part of a “named” lecture series:

Cu-64 Agents For Prevention of Tumor Growth in an Animal Model: Monitoring Therapy Response with microPET and MRI. 21<sup>st</sup> Annual Rupert B. Turnbull Memorial Lecture Series, Washington University School of Medicine, St. Louis, MO, Nov 2, 2001.

Interferon regulatory factor 1 and interferon regulatory factor 2 expression in breast cancer tissue microarrays. Moses Gunn Annual Research Conference, Ann Arbor, MI, April 30, 2004.

## **OTHER PRESENTATIONS**

5<sup>th</sup> International Conference on Experimental Laparoscopic Surgery, Zurich, Switzerland April 2001

Co-Chaired Session: “Experimental Laparoscopic Surgery with Tumor Models.”  
Invited participant Round Table discussion that concluded this meeting.

6<sup>th</sup> International Conference on Experimental Laparoscopic Surgery, New York, New York,  
Spring 2002

Invited participant Round Table discussion that concluded this meeting.

**COMMITTEE AND ADMINISTRATIVE SERVICE**

University of Michigan Comprehensive Cancer Center Member  
Breast Oncology Program, 2003-present.

Washington University School of Medicine:  
Siteman Cancer Center Full Member, 1997-2002  
Focus: Tumor Immunology  
Oncologic Imaging

Protocol Review and Monitoring Committee 2001-2002  
Committee on Complementary and Alternative Medicine 2001-2002  
Animal Care Committee, 1997 - 2000

Barnes-Jewish Hospital  
Animal Care Committee, 1983 - 1997

**PATENTS AND MISCELLANY****Investigational New Drugs:**

I was a major contributor to the data accrual, writing and assembly of the following INDs, all of which were approved by the FDA under Dr. Gordon Philpott's name. The hybridoma cell line producing MAb 1A3 was developed in my lab at Washington University and 15 g of clinical grade agent was purified by In Vitro Corp (St. Louis, MO).

1. <sup>111</sup>In-BröHBED-MAb 1A3 Anti-Colorectal Monoclonal Antibody, submitted March 23, 1990.
2. <sup>64</sup>Cu-benzyl-TETA-MAb 1A3 Anti-colorectal Monoclonal Antibody, submitted March 6, 1992.
3. <sup>64</sup>Cu-benzyl-TETA-1A3 F(ab')<sub>2</sub> Anti-colorectal Monoclonal Antibody, submitted May 27, 1994.
4. <sup>123</sup>I-1A3 F(ab')<sub>2</sub> Anti-colorectal Monoclonal Antibody, submitted January 16, 1995.

**Production of Clinical Grade MABs:**

Under my direction our laboratory generated 2 grams of clinical grade MAb 1A3 F(ab')<sub>2</sub> for use in 2 of the above IND trials. This was accomplished in our surgery research laboratory and required an intensive year and a half of creating a closed system to prevent contamination from occurring, substantial scale-up of our usual MAb purification techniques, and the generation of 55 worksheets to detail each step of the protocol. After purification of the fragment extensive quality control experiments were performed and documented. This agent was approved for use in clinical trials by the FDA.

**BIBLIOGRAPHY***Peer-Reviewed Publications*

1. **Connett JM**, Fleischman JB. Non-histone chromosomal proteins from immunoglobulin producing mouse plasmacytoma parental and variant cell lines. *Molec Immunol* 1981; **18**:573-587.
2. Unger EC, Totty WG, Neufeld D, Otsuka F, Welch MJ, **Connett JM**, Philpott GW. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. *J Invest Radio* 1985; **20**:693-700.
3. Fenwick JR, Philpott GW, **Connett JM**. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAB) 1A3: the influence of administered MAB dose on tumor uptake. *Intl. J Canc* 1989; **44**:1017-1027.
4. Welch MJ, Mathias CJ, Sun Y, Dilley WG, Seesko H, Wells SA Jr., Philpott GW, **Connett JM**, Martell AE. B(2-Hydroxy-3,5-Methylbenzyl)-N'-(2-Hydroxy-5-bromoacetamidobenzyl-ethylene-diamine-N',N'diacetic acid: a new bifunctional chelate for radiolabeling antibodies. *J Lab Comp Radiopharm* 1989; **26**:305-307.
5. Mathias CJ, Sun Y, Welch MJ, **Connett JM**, Philpott GW, Martell AE. A new bifunctional chelate, BrMe<sub>2</sub>HBED: an effective conjugate for radiometals and antibodies. *Inorg Chem* 1990; **29**:1475-1480.
6. Mathias CJ, Sun Y, Welch MJ, **Connett JM**, Philpott GW, Martell AE. N,N'-bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2-ethylenediamine-N-N'diacetic acid, Br<sup>o</sup>HBED: a new bifunctional chelate for radiolabeling antibodies. *Bioconj Chem* 1990; **1**:204-211.
7. Fleischman JW, **Connett JM**, Neufeld DM, Garvin TJ, Philpott GW. Tumor localization and radioimaging with mixtures of monoclonal antibodies directed to different colon cancer associated antigens. *Nucl Med Bio* 1992; **19**:659-668.
8. Mathias C, Welch MJ, Perry D, McGuire A, Zhu X, **Connett JM**, Green M. Investigation of copper PTSM as a PET tracer for tumor blood flow. *Nucl Med Bio* 1991; **18**:807-811.
9. Anderson CJ, **Connett JM**, Schwarz SW, Rocque PA, Guo LW, Philpott GW, Zinn KR, Meares CF, Welch MJ. Copper-64 labeled antibodies for PET imaging. *J Nucl Med* 1992; **33**:1685-1691.
10. Philpott GW, Siegel BA, Schwarz SW, **Connett JM**, Rocque BS, Fleischman JW, Wallis JW,

- Baumann ML, Sun Y, Martell AE, Welch MJ. Immunoscintigraphy with a new <sup>111</sup>In-labeled monoclonal antibody (MAb 1A3) in patients with colorectal cancer. *Dis Colon Rect* 1994; **37**:782-792.
11. Schwarz SW, **Connett JM**, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch, MJ. Evaluation of a direct method for technetium labeling intact and F(ab')<sub>2</sub> 1A3 an anti colorectal monoclonal antibody. *Nucl Med Biol* 1994; **21**: 619-626.
  12. Anderson CJ, Rogers BE, **Connett JM**, Guo LW, Schwarz SW, Zinn KR, Welch MJ. Comparison of two bifunctional chelates for labeling <sup>64</sup>Cu to MAB 1A3 and 1A3 F(ab')<sub>2</sub>: chemistry and animal biodistribution. *J Lab Comp Radiopharm* 1994; **35**:313-315.
  13. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, **Connett JM**, Zinn KR, Meares CF, Cutler PD, Welch MJ, Siegel BA. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. *J Nucl Med* 1995; **36**:1818-1824.
  14. Jones DB, Guo LW, Reinhard MK, Soper NJ, Philpott GW, **Connett JM**, Fleshman JW. The impact of pneumoperitoneum on trocar site implantation of a colon cancer in a hamster model. *Dis Colon Rect* 1995; **38**:1182-1188.
  15. Cutler PD, Schwarz SW, Anderson CJ, **Connett JM**, Welch MJ, Philpott GW, Siegel BA. Dosimetry of <sup>64</sup>Cu-labeled monoclonal antibody 1A3 as determined by pet imaging of the torso. *J Nucl Med* 1995; **36**:2363-2371.
  16. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, **Connett JM**, Welch MJ. Identification of metabolites of In-111-DTPA-monoclonal antibodies and antibody fragments *in vivo*. *Canc Res (suppl)* 1995; **55**:5714s-5720s..
  17. **Connett JM**, Anderson CJ, Guo LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ. Radioimmunotherapy with a Cu-64 labeled monoclonal antibody: a comparison with Cu-67. *PNAS* 1996; **93**:6814-6818.
  18. Rogers BE, Anderson CJ, **Connett JM**, Guo LW, Edwards WB, Sherman ELC, Zinn KR, Welch MJ. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. *Bioconjugate Chem* 1996; **7**:511-522.
  19. Wu JS, Brasfield EB, Guo LW, Ruiz M, **Connett JM**, Philpott GW, Jones DJ, Fleshman JW. Implantation of colon cancer at trocar sites is increased by low pressure pneumoperitoneum. *Surgery* 1997; **122**: 1-7.
  20. Wu JS, Jones DB, Guo LW, Brasfield EB, Ruiz MB, **Connett JM**, Fleshman JW. Effects of pneumoperitoneum on tumor implantation with decreasing inoculum of tumor. *Dis Colon*



Rect 1998; **41**:141-146.

21. Wu JS, Guo LW, Ruiz MB, Pfister SM, **Connett JM**, Fleshman, JW. Excision of trocar sites reduces tumor implantation in an animal model. *Dis Colon Rect* 1998; **41**: 1107-1111.
22. Wu JS, Pfister SM, Ruiz MB, **Connett JM**, Fleshman JW. Local treatment of abdominal wound reduces tumor implantation. *J Surg Oncology* 1998; **69**: 9-14.
23. Underwood RA, Wu JS, Wright MP, Ruiz MB, Pfister SM, **Connett JM**, Fleshman JW. Sodium hyaluronate carboxymethylcellulose based bioresorbable membrane (Seprafilm™) - does it affect tumor implantation at abdominal wound sites? *Dis Colon Rectum* 1999; **42**:614-619.
24. **Connett JM**, Buettner TL, Anderson CJ. Maximum tolerated dose and large tumor radioimmunotherapy studies of <sup>64</sup>Cu-labeled MAB 1A3 in a colon cancer model. *Clinical Cancer Res* 1999; **5**:3207-3210.
25. Lewis JS, Laforest R, Buettner TL, Song SK, Fujibayashi Y, **Connett JM**, Welch MJ. Copper-64-diacetyl-bis(N<sup>4</sup>-methylthiosemicarbazone)(<sup>64</sup>Cu-ATSM)-an agent for radiotherapy. *PNAS* 2000; **98**:1206-1211.
26. Lewis MR, Boswell CA, Laforest R, Buettner TL, Ye D, **Connett JM**, Anderson CJ. Conjugation of monoclonal antibodies with TETA using activated esters: Biological comparison of <sup>64</sup>Cu-TETA-1A3 with <sup>64</sup>Cu-BAT-2IT-1A3. *Cancer Biotherapy and RadioPharm* 2002; **16**:483-494.
27. Lewis JS, **Connett JM**, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ. <sup>64</sup>Cu-PTSM for the prevention of tumor growth at wound sites following laparoscopic surgery: Monitoring therapy response with microPET and MRI. *Cancer Res* 2002; **62**:445-449.
28. Yim JH, Ro SH, Lowney JK, Wu SJ, **Connett JM**, Doherty, GM. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in Interferon-gamma growth inhibition of human breast carcinoma cell lines. *Journal of Interferon and Cytokine Research* 2003; **23**:501-512.
29. **Connett JM**, Hunt SR, Hickerson SM, Wu SJ, Doherty GM. Localization of interferon-gamma activated Stat1 and interferon regulatory factors 1 and 2 in breast cancer cells. *Journal of Interferon and Cytokine Research* 2003: **23**:621-630.
30. **Connett JM**, Badri LN, Bingham EL, Doherty GM. Interferon- $\gamma$  priming of breast cancer cell lines in Fas and TRAIL death receptor mediated apoptosis. *Proceedings of the 5<sup>th</sup> Joint Meeting of the International Cytokine Society and International Society for Interferon and*

Cytokine Research 2004.

31. Halpin VJ, Underwood RA, Ye D, Cooper DH, Wright S, Hickerson SM, Connett WC, **Connett JM**, Fleshman JW. Pneumoperitoneum does not influence trocar site implantation during tumor manipulation in a solid tumor model. *Surg Endosc* 2005; **19**: 1636-1640.
32. **Connett JM**, Badri LN, Giordano TJ, Connett WC, Doherty GM. Interferon regulatory factor (IRF-1) and interferon regulatory factor 2 (IRF-2) expression in breast cancer tissue microarrays. *Journal of Interferon and Cytokine Research* 2005;**25**:587-594.
33. Osuchowski MF, **Connett JM**, Welch K, Granger J, Remick DG. Stratification is the key: Inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. *Critical Care Med* (in press).

*Abstracts, Preliminary Communications, Clinical Papers*

1. Garvin TJ, Philpott GW, **Connett JM**: Fc mediated binding of murine monoclonal antibodies (MAbs) to human granulocytes. *Proceedings of American Association for Cancer Research*, **25**:261, 1984.
2. Margraf HW, Garvin TJ, **Connett JM**, Philpott GW: Silver-monoclonal antibody complexes; potential new immunotoxins. *Proceedings of American Association for Cancer Research*, **25**:1460, 1984.
3. **Connett JM**, Fenwick JR, Timmcke A, Philpott GW: Characterization of the binding properties of murine monoclonal antibody (MAB)1A3, a newly described antibody displaying anti-human colon cancer selectivity. *Proceedings of the American Association for Cancer Research*, **28**:352, 1987.
4. Timmcke A, **Connett JM**, Fleshman JW, Jr, Neufeld D, Shemesh E, Philpott GW: Improved specific binding to human colon carcinoma using combinations of monoclonal antibodies (MAbs). *Proceedings of the American Association for Cancer Research*, **28**:362, 1987.
5. **Connett JM**, Inkster MD, Ruiz MB, Philpott GW: Further characterization of murine monoclonal antibody (MAB) 1A3, and antibody displaying anti-human colon cancer selectivity. *Proceeding of the American Association for Cancer Research*, **29**:384, 1988.
6. Sun YZ, Mathias CJ, Welch MJ, **Connett JM**, Philpott GW, Martell AE: Development and evaluation of a new bifunctional chelate to radiolabel antibodies. *Journal of Nuclear Medicine*, **29**:814, 1988.
7. Welch MJ, Mathias CJ, Moerlein SM, **Connett JM**, Philpott GW: Radioiodinated tyrosine-cellobiose (TC) labeling of monoclonal antibodies (MAbs): Comparison with lactoperoxidase

- (LP) labeling. *Journal of Nuclear Medicine*, **29**:835, 1988.
8. Mathias CJ, Sun YZ, Welch MJ, **Connett JM**, Philpott GW: BröHBED: An improved bifunctional chelate for radiolabeling antibodies. *Journal of Nuclear Medicine*, **30**:763, 1989.
  9. **Connett JM**, Ruiz MB, Germain CJ, Fenwick JJ, Philpott GW: *In vitro* and *in vivo* characterization studies of anti-human colon cancer murine monoclonal antibodies (MAb)1A3 and 5A4. *Proceedings of the American Association for Cancer Research*, **30**:346, 1989.
  10. **Connett JM**, Mathias CJ, Welch MJ, Zhu X, Philpott GW: Increased uptake of a unique radiolabeled anti-colon cancer monoclonal antibody (MAb 1A3) in younger tumors in a human colon cancer (GW39) xenograft model. *Proceedings of the American Association for Cancer Research*, **30**:359, 1989.
  11. **Connett JM**, Zhu X, O'Halloran LR, Philpott GW: Improved tumor uptake with a mixture of I-125 monoclonal antibodies (MAbs) in a colon cancer model. *Journal of Nuclear Medicine*, **31**:853, 1990.
  12. Philpott GW, Siegel BA, Schwarz SW, Welch MJ, **Connett JM**: Initial clinical study of a new indium-labeled anti-colorectal carcinoma monoclonal antibody (MAb 1A3) in patients with advanced colorectal cancer. *Journal of Nuclear Medicine*, **32**:1054, 1991.
  13. **Connett JM**, Zhu X, O'Halloran LR, Philpott GW: Radioimmunotherapy of human colon carcinoma (GW-39) in hamsters with I-131 anti-colon cancer monoclonal antibody (MAb) 1A3. *Proceedings of American Association for Cancer Research*, **32**:263, 1991.
  14. **Connett JM**, Guo LW, Anderson CJ, Schwarz SW, Welch MJ: Tumor comparison of 125-I- and 64-Cu-anti-colorectal cancer monoclonal antibody 1A3 (MAb 1A3) in a human colon cancer (GW39) animal model. *Proceedings of the American Association for Cancer Research*, **33**:352, 1992.
  15. Philpott GW, Siegel BA, Schwarz SW, Fleshman JW, Jr, Welch MJ, **Connett JM**: Immunoscintigraphy with a new anti-colorectal carcinoma monoclonal antibody (MAb 1A3). *Proceedings of the Society of Colorectal Surgeons*, 1992.
  16. Schwarz, SW, Rocque PA, Anderson CJ, Welch MJ, **Connett JM**, Philpott GW: Preparation, quality control and clinical investigation using 111 In-labeled 1A3, a monoclonal anti-colorectal carcinoma antibody for patients. *Proceedings of the 139th Annual American Pharmacology Association meeting*, 1992.
  17. Philpott GW, Siegel BA, Schwarz SW, Welch MJ, **Connett JM**: Improved tumor detection in patients with rectosigmoid cancer using a new anti-colorectal cancer monoclonal antibody (MAb 1A3). *Proceedings of the American Society of Clinical Oncology*, **11**(Suppl):164, 1992.

18. Anderson CJ, Schwarz SW, Rocque PA, Anderson CJ, Welch MJ, **Connett JM**, Philpott GW, Zinn KR, Meares CF, Welch MJ: Copper labeled antibodies for PET imaging. *Journal of Laboratory Compounds in Radiopharmacology*, 368-369, 1993.
19. Schwarz SW, Rocque PA, Anderson CJ, Welch MJ, **Connett JM**, Philpott GW: Evaluation direct method for technetium labeling intact and F(ab')<sub>2</sub> 1A3 an anti-colorectal monoclonal antibody. *Journal of Laboratory Compounds in Radiopharmacology*, 404-406, 1993.
20. Anderson CJ, Schwarz SW, **Connett JM**, Rocque PA, Guo LW, Zinn KR, Philpott GW, Welch MJ: Optimization of the preparation of Cu-64 labeled monoclonal antibody (MAb) fragments (1A3-F(ab')<sub>2</sub>) for improved biodistribution. *Journal of Nuclear Medicine*, **34**:28P, 1993.
21. Anderson CJ, **Connett JM**, Baumann ML, Schwarz SW, Zinn KR, Philpott GW, Welch MJ: Cu-67 and Cu-64 labeled-monoclonal antibody (MAb) 1A3 as potential agents for radioimmunotherapy. *Journal of Nuclear Medicine*, **34**:134P, 1993.
22. **Connett JM**, Anderson CJ, Baumann ML, Schwarz SW, Zinn KR, Philpott GW, Welch MJ: Cu-67 and Cu-64 labeled-monoclonal antibody (MAb) 1A3 as potential agents for radioimmunotherapy. *Journal of Nuclear Medicine*, **34**:216P, 1993.
23. Philpott GW, Schwarz SW, Anderson CJ, Griffeth LK, **Connett JM**, Zinn KR, Meares CF, Siegel BA, Welch MJ: Initial clinical study of Cu-64-labeled anti-colon cancer monoclonal antibody (MAb) 1A3. *Proceedings of American Association for Cancer Research*, **34**:81P, 1993.
24. **Connett JM**, Guo LW, Anderson CJ, Welch MJ, Philpott GW: Radioimmunotherapy of human colon carcinoma (GW-39) in hamsters with Cu-67 anti-colon cancer monoclonal antibody (MAb) 1A3. *Proceedings of American Association for Cancer Research*, **35**:648, 1994.
25. Rogers BE, Franano FN, Edwards WB, **Connett JM**, Anderson CJ, Duncan Jr, Welch MJ: Identification of metabolites of IN-111-DTPA-monoclonal antibodies and antibody fragments *in vivo*. *Journal of Immunotherapy*, **16**:165, 1994.
26. Anderson CJ, Rogers BE, **Connett JM**, Guo LW, Schwarz SW, Zinn KR, Welch MJ: Comparison of two bifunctional chelates for labeling 65-Cu to MAb 1A3-F(ab')<sub>2</sub>: chemistry and animal biodistribution. *Journal of Laboratory Compounds in Radiopharmacology*, **37**:313-315, 1994.
27. Philpott GW, Dehdashti F, Schwarz SW, **Connett JM**, Anderson CJ, Zinn KR, Meares CF, Siegel BA, Welch MJ: Positron emission tomography (PET) with Cu-64-labeled monoclonal

- antibody (MAb 1A3) in colorectal cancer. *Journal of Nuclear Medicine*, **35**:12P, 1994.
28. Anderson CJ, **Connett JM**, Guo LW, Schwarz SW, Philpott GW, Zinn KR, Welch MJ: Initial comparison of Cu-67 and Cu-64-labeled anti-colorectal carcinoma MAb 1A3 as agents for radioimmunotherapy in tumor-bearing hamsters. *Journal of Nuclear Medicine*, **35**:161P, 1994.
  29. Philpott GW, Dehdashti F, Schwarz SW, **Connett JM**, Anderson CJ, Zinn KR, Siegel BA, Welch MJ, Meares CF: Clinical potential of a new tumor imaging method by positron emission tomography (PET) with Cu-64-labeled monoclonal antibody (MAb 1A3) in rectosigmoid cancer patients. *Proceedings of the American Society of Clinical Oncology*, **13**:201, 1994.
  30. Philpott GW, Dehdashti F, Schwarz SW, **Connett JM**, Anderson CJ, Zinn KR, Cutler PD, Welch MJ, Siegel BA: Radioimmunopet (MAb-PET) with Cu-64-labeled monoclonal antibody (MAb 1A3) fragments [F(ab')<sub>2</sub>] in patients with colorectal cancers. *Journal of Nuclear Medicine*, **36**:9P, 1995.
  31. **Connett JM**, Guo LW, Anderson CJ, Schwarz SW, Zinn KR, Philpott GW, Welch MJ: *In vivo* toxicity and long-term radioimmunotherapy studies of Cu-64 and Cu-67 anti-colon carcinoma monoclonal antibody (MAb)-1A3 in the GW39-hamster model. *Journal of Nuclear Medicine*, **36**:92P, 1995.
  32. Anderson CJ, **Connett JM**, Schwarz SW, Guo LW, Baumann ML, Zinn KR, Welch MJ: Comparison of radioimmunotherapy (RIT) in colorectal tumor-bearing hamsters with Cu-64 and Cu-67 labeled MAb 1A3. *Journal of Nuclear Medicine*, **36**:217P, 1995.
  33. Schwarz SW, Cutler PD, Eichling JI, Anderson CJ, **Connett JM**, Guo LW, Philpott GW, Siegel BA, Welch MJ: Tumor dosimetry for Cu-64 and Cu-67-labeled MAb 1A3 for radioimmunotherapy. *Journal of Nuclear Medicine*, **36**:181P, 1995.
  34. **Connett JM**, Anderson CJ, Guo LW, Schwarz SW, Germain CJ, Philpott GW, Welch MJ: Long-term radioimmunotherapy studies of Cu-64 anti-colon carcinoma monoclonal antibody (MAb)-1A3, intact and F(ab')<sub>2</sub>, singly and in combination in the GW39-hamster model. *Journal of Nuclear Medicine*, **37**:61P, 1996.
  35. Anderson CJ, **Connett JM**, Germain CJ, Guo LW, Rogers BE, Schwarz SW, Fritzberg AR, Welch MJ: Cu-64-labeled BAT-2IT-NR-LU-10 Fab: an agent for PET imaging and radioimmunotherapy. *Journal of Nuclear Medicine*, **37**:95P, 1996.
  36. Anderson CJ, **Connett JM**, Lewis JS, McCarthy DW, Welch MJ. Copper-64-labeled radiopharmaceuticals for PET imaging and radiotherapy. *Conference Proc of 15<sup>th</sup> International Conference of Accelerators in Research and Industry*, 1999.

37. **Connett JM**, Buettner TL, Schwarz SW, Anderson CJ. *In vivo* toxicity and radioimmunotherapy studies comparing Cu-64 and I-131 labeled anti-colon carcinoma monoclonal antibody (Mab)-1A3 in the GW39 hamster model. *J Nucl Med*, **39**:105P, 1998.
38. **Connett JM**, Buettner TL, McCarthy DW, Anderson CJ. Maximum tolerated dose studies in hamsters with Cu-64-BAT-2IT Mab 1A3, an anti-human colorectal cancer Mab. *Eur J Nucl Med*, **25**:934, 1998.
39. Buettner TL, Lewis MR, Bisbee C, Raubitschek A, Anderson CJ, **Connett JM**. Biodistribution studies in hamsters carrying human colon cancer comparing Cu-64-DOTA-labeled Mab-1A3 and Mab-cT84.66. Conference Proc of 11<sup>th</sup> International Symposium on Radiopharmacology, 1999.
40. Anderson CJ, **Connett JM**, Lewis JS, McCarthy DW, Welch MJ. Copper-64-labeled radiopharmaceuticals for PET imaging and radiotherapy. Conference Proc of 15<sup>th</sup> International Conference of Accelerators in Research and Industry, 1999.
41. **Connett JM**, Hickerson SM, Ye D, Wright MP, Cooper DH, Buettner TL, Underwood RA, Fleshman JW. Effects of Seprafilm on tumor implantation at trocar sites. Proceedings of the 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, **4**:9, 2000.
42. **Connett JM**, Underwood RA, Hickerson SM, Wright MP, Persons E, Buettner TL, Ye D, Fleshman JW. Implantation of GW39 human colon cancer cells at hamster wound sites as a function of cell inoculum and Seprafilm barriers. Proceedings of the 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, **4**:10, 2000.
43. **Connett JM**, Buettner TL, Ye D, Hickerson SM, Person E, Fleshman JW. Radioimmunotherapy of GW39 human colon cancer cells in a laparoscopic surgery hamster model. Proceedings of the 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, **4**:11, 2000.
44. Halpin VJ, Underwood RA, **Connett JM**, Ye D, Cooper DH, Wright MP, Hickerson SM, Connett WC, Fleshman JW. Impact of tumor manipulation on trocar site implantation of colon cancer in a hamster model. Proceedings of the 4<sup>th</sup> International Conference of Experimental Laparoscopic Surgery, **4**:14, 2000.
45. Lewis JS, **Connett JM**, Buettner TL, Fujibayashi Y, Welch MJ. <sup>64</sup>Cu-bis(thiosemicarbazone) complexes as agents for diagnosis and radiotherapy. 2000 International Chemical Congress of Pacific Basin Societies, MEDI 0341, 2000.
46. Lewis JS, **Connett JM**, Buettner TL, Ye D, Hickerson SM, Fujibayashi Y, Fleshman JW, Welch MJ. <sup>64</sup>Cu-Pyruvaldehyde-*bis*(N4-methylthiosemicarbazone)(<sup>64</sup>Cu-PTSM) as a

- radiotherapy agent to prevent the growth of tumors at wound sites following laparoscopy. *European Journal of Nuclear Medicine*, **8**:952P,2000.
47. Song S-W, Lewis JS, **Connett JM**, Buettner TL, Welch MJ, Ackerman JJH. Serial evaluation of radiotherapy of GW39 tumor bearing hamsters using PET/MRI. Workshop on MR in Experimental & Clinical Cancer Research in the New Millennium, Norway 2000.
  48. **Connett JM**, Underwood RA, Hickerson SM, Wright M, Persons E, Buettner TL, Ye D, Fleshman JW. Implantation of GW39 human colon cancer cells in hamster wound sites as a function of cell inoculum and Seprafilm barriers. *Proceedings of the Society of Surgical Oncology*, 2000.
  49. **Connett JM**, Hunt SR, Hickerson SM, Doherty GM. Interferon-gamma upregulation of Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. *Conference Proceedings of International Symposium on Cancer Vaccines*, p30, 2000.
  50. Lewis JS, **Connett JM**, Buettner TL, Ye D, Hickerson SM, Fujibayashi Y, Fleshman JW, Welch MJ.  $^{64}\text{Cu}$ -pyruvaldehyde-*bis*(N4-methylthiosemicarbazone)( $^{64}\text{Cu}$ -PTSM) as a radiotherapy agent to prevent the growth of tumors at wound sites following laparoscopy. *European Journal of Nuclear Medicine*, **8**:952P, 2000.
  51. **Connett JM**, Hickerson SM, Ye D, Wright M, Cooper DH, Buettner TL, Underwood RA, Fleshman JW. Effects of Seprafilm on tumor implantation at trocar sites. *Dis Colon Rect*, **43**:A60, 2000.
  52. Lewis JS, Buettner TL, **Connett JM**, Fujibayashi Y, Welch MJ.  $^{64}\text{Cu}$ -ATSM as a radiotherapeutic agent: extended survival in GW39 tumor-bearing hamsters. *Journal of Nuclear Medicine*, **41**:115P, 2000.
  53. **Connett JM**, Lewis JS, Garbow JR, Ackerman JH, Hickerson SM, Buettner TL, Fleshman JW, Welch MJ. Combined Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) characterization of abdominal tumors in a hamster laparoscopic model of colorectal cancer. *Proceedings of the 5<sup>th</sup> International Conference of Experimental Laparoscopic Surgery*, **5**:19, 2001.
  54. Halpin VJ, Underwood RA, Ye D, Cooper DH, Wright M, Hickerson SM, Connett WC, **Connett JM**, Fleshman JW. Pneumoperitoneum does not influence trocar site implantation during tumor manipulation in a solid tumor model. *Surgical Endoscopy*, **15**: s131, 2001.
  55. **Connett JM**, Lewis JS, Garbow JR, Hickerson SM, Buettner TL, Fujibayashi Y, Welch MJ, Fleshman JW.  $^{64}\text{Cu}$ -PTSM as an inhibitor of tumor recurrence in a colorectal cancer laparoscopic model. *Proceedings of the 5<sup>th</sup> International Conference of Experimental Laparoscopic Surgery*, **5**:22, 2001.

56. **Connett JM**, Hunt SR, Hickerson SM, Doherty GM. Interferon-gamma upregulation of Stat1 and Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. *J Interferon Cytokine Res*, **21**:s105, 2001.
57. **Connett JM**, Hunt SR, Hickerson SM, Doherty GM. Interferon-gamma upregulation of Stat1 and Interferon regulatory factors 1 and 2 in breast cancer cells using confocal microscopy. *Proc Amer Assn Canc Res*, **42**:501, 2001.
58. Lewis JS, **Connett JM**, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ. <sup>64</sup>Cu-PTSM as an inhibitor of tumor recurrence. *Journal of Labeled Compounds and Radiopharmaceuticals*, **44**:87-89, 2001.
59. **Connett JM**, Lewis JS, Garabow JR, Buettner TL, Fujibayashi Y, Welch MJ, Fleshman JW. Cu-64 PTSM for the prevention of tumor growth at wound sites following laparoscopic surgery: Monitoring therapy response with microPET and MRI. *6<sup>th</sup> International Conference of Experimental Laparoscopic Surgery*, **6**:13, 2002.
60. Ye D, Moran K, Fleshman JW, **Connett JM**: Effect of intraperitoneal fibrinolytic therapy on tumor implantation in wound sites. *6<sup>th</sup> International Conference of Experimental Laparoscopic Surgery*, **6**:15, 2002.
61. **Connett JM**, Hickerson SM, Doherty GM. Confocal microscopy detection of STAT1 and IRF-1 and -2 upregulation by *ex vivo* IFN- $\gamma$  in fresh human breast cancer tissue. *Proc Amer Assn Canc Res*, **43**:437, 2002.
62. **Connett JM**, Lee E, Hickerson SM, Doherty GM. The role of Fas in interferon-gamma mediated growth inhibition and apoptosis in human breast cancer cells. *Proc Amer Assn Canc Res*, **44**:496, 2003.
63. **Connett JM**, Badri LN, Bingham EL, Doherty GM. Interferon- $\gamma$  priming of breast cancer cell lines in Fas death receptor mediated apoptosis.. *Proc Amer Assn Canc Res* **45**:3572, 2004.